<DOC>
	<DOC>NCT00914654</DOC>
	<brief_summary>The purpose of the study is to assess the blood and urine concentrations of inhaled formoterol.</brief_summary>
	<brief_title>Concentrations of Formoterol in Blood and Urine</brief_title>
	<detailed_description>The purpose of the study is to assess the serum and urine concentrations after inhalation of 18 microgram formoterol as one dose. Furthermore to investigate the serum and urine concentrations of inhaled formoterol and evaluate the difference between three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Physiciandiagnosed asthma with positive reversibility or challenge test. Informed consent. Age between 1845 years. Sex: male. Asthma classified as mild to moderate according to GINA guidelines. Used beta2agonist in minimum 12 months. Smokers or exsmokers with a smoking history of 10 pack years or more. Respiratory tract infections within the last 2 weeks prior to study day. Subjects with other chronic diseases than asthma and allergy. Allergy towards the study medicine. Use of beta2agonist 10 days prior to study day.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Doping</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Urinary concentrations</keyword>
	<keyword>Beta-agonists</keyword>
</DOC>